Paper42864652PubMed
CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML.
Noer MG and 12 others. Genome Med, 2026.
Cite this record
ConductScience Library. CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML. Papers, record 42864652. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42864652
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML.
- Journal
- Genome Med
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-15
Source PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| fms-Like Tyrosine Kinase 3 | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| T-Lymphocytes | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| CRISPR-Cas Systems | Major topic |
| Genetic Loci | Major topic |
| Humans | |
| Animals | |
| Mice | |
| Cell Line, Tumor |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 4-1612-391/1 | The Danish health authorities (SST) | PubMed | ||
| 101041231 | HORIZON EUROPE European Research Council | PubMed | ||
| 101057438 | Horizon 2020 | PubMed | ||
| R238-2016-3349 | Lundbeck Foundation | PubMed | ||
| NNF19OC0058238 | Novo Nordisk Fonden | PubMed | ||
| 8056-00010B | Innovationsfonden | PubMed | ||
| CF20-0424 | Carlsbergfondet | PubMed |
Source PubMed
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19561539 | Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. | J Immunother | 2009 | https://conductscience.org/library/papers/19561539 | PubMed |
| 2 | 39833408 | Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. | Nat Med | 2025 | https://conductscience.org/library/papers/39833408 | PubMed |
| 3 | 37365642 | Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37365642 | PubMed |
| 4 | 40181544 | CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes. | Mol Ther | 2025 | https://conductscience.org/library/papers/40181544 | PubMed |
| 5 | 32527933 | 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32527933 | PubMed |
| 6 | 35130342 | Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. | Blood Adv | 2022 | https://conductscience.org/library/papers/35130342 | PubMed |
| 7 | 32241852 | Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation. | Haematologica | 2021 | https://conductscience.org/library/papers/32241852 | PubMed |
| 8 | 28496177 | Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. | Leukemia | 2017 | https://conductscience.org/library/papers/28496177 | PubMed |
| 9 | 37794590 | Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. | Cell | 2023 | https://conductscience.org/library/papers/37794590 | PubMed |
| 10 | 29716633 | Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells. | J Hematol Oncol | 2018 | https://conductscience.org/library/papers/29716633 | PubMed |
| 11 | 32518207 | Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia. | Mol Cancer Ther | 2020 | https://conductscience.org/library/papers/32518207 | PubMed |
| 12 | 39946666 | Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies. | J Clin Oncol | 2025 | https://conductscience.org/library/papers/39946666 | PubMed |
| 13 | 31088841 | Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. | Cancer Discov | 2019 | https://conductscience.org/library/papers/31088841 | PubMed |
| 14 | 28956530 | Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6. | Elife | 2017 | https://conductscience.org/library/papers/28956530 | PubMed |
| 15 | 39300079 | Current status and research directions in acute myeloid leukemia. | Blood Cancer J | 2024 | https://conductscience.org/library/papers/39300079 | PubMed |
| 16 | 38583184 | CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. | Cancer Discov | 2024 | https://conductscience.org/library/papers/38583184 | PubMed |
| 17 | 40367950 | Emerging trends in clinical allogeneic CAR cell therapy. | Med | 2025 | https://conductscience.org/library/papers/40367950 | PubMed |
| 18 | 39013470 | Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. | Cell | 2024 | https://conductscience.org/library/papers/39013470 | PubMed |
| 19 | 37330575 | Biomarkers as targets for CAR-T/NK cell therapy in AML. | Biomark Res | 2023 | https://conductscience.org/library/papers/37330575 | PubMed |
| 20 | 32014868 | Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32014868 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42864652
GET https://conductscience.org/api/papers/v1/42864652/references?page=2